Compare ANIX & CALC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ANIX | CALC |
|---|---|---|
| Founded | 1982 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 104.0M | 88.3M |
| IPO Year | 2013 | 2020 |
| Metric | ANIX | CALC |
|---|---|---|
| Price | $2.55 | $0.57 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 2 |
| Target Price | $8.67 | ★ $10.00 |
| AVG Volume (30 Days) | 88.7K | ★ 427.7K |
| Earning Date | 03-09-2026 | 03-03-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 12.82 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $210,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.33 | $0.46 |
| 52 Week High | $5.46 | $7.20 |
| Indicator | ANIX | CALC |
|---|---|---|
| Relative Strength Index (RSI) | 34.14 | 32.73 |
| Support Level | N/A | $0.49 |
| Resistance Level | $3.10 | $0.79 |
| Average True Range (ATR) | 0.20 | 0.08 |
| MACD | -0.02 | 0.06 |
| Stochastic Oscillator | 13.49 | 9.38 |
Anixa Biosciences Inc a cancer-focused biotechnology company, develops vaccines and therapies that are focused on critical unmet needs in oncology. The company is developing both diagnostics and therapeutics to detect cancer early, which is curable, and to treat those afflicted once diagnosed. Its segment includes CAR-T Therapeutics; Cancer Vaccines; Anti-Viral Therapeutics and others.
CalciMedica Inc is a clinical-stage biopharmaceutical company focused on developing therapeutics that treat serious illnesses driven by inflammatory and immunologic processes and direct cellular damage. Its product candidates act upon calcium release-activated calcium (CRAC) channels and would constitute a new class of drugs. Its product candidate is Auxora, a potent and selective intravenous formulated small molecule CRAC channel inhibitor containing the active compound zegocractin (formerly referred to as CM4620) that, in animal models, reduced acute epithelial and/or endothelial cell injury and inflammation in organs, such as the pancreas, lungs and kidneys.